From: O223 Antiretroviral Pregnancy Registry (APR) at 10,000 prospective reports
 | Defects | LB Prevalence (95%CI) |
---|---|---|
Zidovudine | 87/2808 | 3.1% (2.5%,3.8%) |
Lamivudine | 85/2784 | 3.1% (2.4%,3.8%) |
Nelfinavir | 33/972 | 3.4% (2.3%,4.7%) |
Nevirapine | 18/737 | 2.4% (1.5%,3.8%) |
Stavudine | 19/651 | 2.9% (1.8%,4.5%) |
Ritonavir | 16/628 | 2.5% (1.5%,4.1%) |
Abacavir | 17/512 | 3.3% (1.9%,5.3%) |
Tenofovir | 11/491 | 2.2% (1.1%,4.0%) |
Efavirenz | 10/364 | 2.7% (1.3%,5.0%) |
Didanosine | 16/353 | 4.5% (2.6%,7.3%) |
Lopinavir | 6/328 | 1.8% (0.7%,3.9%) |
Indinavir | 6/272 | 2.2% (0.8%,4.7%) |